Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SRZN 
Surrozen Inc (SRZN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SRZN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $37
1 Year Target Price $37
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -74.92% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 100.10M USD | Price to earnings Ratio - | 1Y Target Price 37 |
Price to earnings Ratio - | 1Y Target Price 37 | ||
Volume (30-day avg) 2 | Beta 0.6 | 52 Weeks Range 5.90 - 18.17 | Updated Date 08/29/2025 |
52 Weeks Range 5.90 - 18.17 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.82 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date 2025-08-08 | When - | Estimate -1.07 | Actual 0.85 |
Profitability
Profit Margin -132.3% | Operating Margin (TTM) -917.29% |
Management Effectiveness
Return on Assets (TTM) -21.93% | Return on Equity (TTM) -62.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 17225746 | Price to Sales(TTM) 7.93 |
Enterprise Value 17225746 | Price to Sales(TTM) 7.93 | ||
Enterprise Value to Revenue 1.36 | Enterprise Value to EBITDA 0.71 | Shares Outstanding 8570360 | Shares Floating 4798285 |
Shares Outstanding 8570360 | Shares Floating 4798285 | ||
Percent Insiders 4.09 | Percent Institutions 71.27 |
Upturn AI SWOT
Surrozen Inc
Company Overview
History and Background
Surrozen Inc. was founded in 2016 and focused on developing antibody-based therapeutics to selectively activate the Wnt signaling pathway for tissue repair and regeneration. It later merged with Consonance-HFW Acquisition Corp in 2022 to become a publicly traded company.
Core Business Areas
- Regenerative Medicine: Surrozen develops and tests regenerative medicines based on activating the Wnt pathway to repair damaged tissues. This includes treatments for liver diseases, inflammatory bowel disease, and other indications with significant unmet needs.
Leadership and Structure
The leadership team consists of key executives focused on research and development, clinical trials, and business operations. Specific names and organizational charts require further research.
Top Products and Market Share
Key Offerings
- SZN-1326: A clinical-stage Wnt mimetic antibody designed to target and expand Lgr5+ stem cells in the intestine for the treatment of inflammatory bowel disease (IBD). Market share data for this specific compound is not readily available as it is in clinical development. Competitors in IBD include companies developing anti-TNF antibodies, JAK inhibitors, and other novel therapies.
- SZN-043: A clinical-stage Wnt mimetic antibody designed to target and expand hepatocytes for the treatment of severe alcoholic hepatitis. Market share information is not readily available. Competing approaches include liver transplantation and supportive care, as well as companies developing anti-inflammatory or anti-fibrotic therapies for liver disease.
Market Dynamics
Industry Overview
The regenerative medicine industry is rapidly growing, driven by advancements in biotechnology and an increasing demand for therapies that can repair and regenerate damaged tissues and organs. Significant investments are being made in research and development, leading to the emergence of novel treatment modalities.
Positioning
Surrozen is positioned as a regenerative medicine company focusing on Wnt signaling pathway activation. Its competitive advantage lies in its antibody-based approach for targeted tissue repair, which, if successful, could offer a more specific and effective therapeutic strategy than existing treatments.
Total Addressable Market (TAM)
The TAM for Surrozen's target indications (IBD, liver diseases) is substantial, potentially reaching billions of dollars annually. Surrozen's success depends on its ability to translate its clinical programs into approved therapies and capture a portion of this market.
Upturn SWOT Analysis
Strengths
- Novel Wnt signaling platform
- Targeted antibody-based approach
- Potential for regenerative therapies
- Clinical-stage assets
Weaknesses
- High clinical trial risk
- Dependence on clinical trial success
- Limited financial resources
- Uncertainty of regulatory approval
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new disease indications
- Advancements in regenerative medicine technologies
- Positive clinical trial data
Threats
- Competition from established therapies
- Regulatory hurdles
- Clinical trial failures
- Patent disputes
Competitors and Market Share
Key Competitors
- BMY
- PFE
- ABBV
- LLY
- AMGN
Competitive Landscape
Surrozen's Wnt signaling platform provides a novel approach to tissue repair, setting it apart from traditional pharmaceutical approaches. However, it faces stiff competition from established pharmaceutical companies with broader therapeutic portfolios and greater financial resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the early stage of the company.
Future Projections: Future growth is highly dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates are speculative and subject to change.
Recent Initiatives: Recent initiatives focus on advancing clinical trials for SZN-1326 and SZN-043.
Summary
Surrozen is an early-stage regenerative medicine company with a novel approach to activating the Wnt signaling pathway for tissue repair. Its potential strengths lie in its innovative technology and clinical-stage assets, but its weaknesses include high clinical trial risk and limited financial resources. The company's future success hinges on positive clinical trial outcomes and potential partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- Third-party market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Financial data and market share estimates are based on available information and may not be precise. Investment decisions should be made based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Surrozen Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-01-11 | CEO, President & Director Mr. Craig C. Parker M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 40 | Website https://www.surrozen.com |
Full time employees 40 | Website https://www.surrozen.com | ||
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.